Bayforest Capital Ltd Makes New $590,000 Investment in LivaNova PLC $LIVN

Key Points

• Bayforest Capital Ltd has acquired 15,033 shares of LivaNova PLC, valued at approximately $590,000, during the first quarter of the year.
• Institutional investors hold a significant share of LivaNova, with approximately 97.64% of the company's stock owned by such entities.
• Analysts are optimistic about LivaNova's stock, with several raising their price targets, resulting in a consensus rating of "Buy" and a target price of around $59.71.

Bayforest Capital Ltd bought a new stake in shares of LivaNova PLC (NASDAQ:LIVN - Free Report) in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor bought 15,033 shares of the company's stock, valued at approximately $590,000.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. GAMMA Investing LLC raised its holdings in LivaNova by 2,299.7% during the 1st quarter. GAMMA Investing LLC now owns 8,759 shares of the company's stock valued at $344,000 after buying an additional 8,394 shares during the period. Two Sigma Advisers LP raised its holdings in LivaNova by 148.5% during the 4th quarter. Two Sigma Advisers LP now owns 214,545 shares of the company's stock valued at $9,936,000 after buying an additional 128,200 shares during the period. EP Wealth Advisors LLC purchased a new stake in LivaNova during the 1st quarter valued at $293,000. Amundi raised its holdings in LivaNova by 7.2% during the 1st quarter. Amundi now owns 196,435 shares of the company's stock valued at $7,362,000 after buying an additional 13,142 shares during the period. Finally, Hsbc Holdings PLC raised its holdings in LivaNova by 13.4% during the 1st quarter. Hsbc Holdings PLC now owns 6,666 shares of the company's stock valued at $258,000 after buying an additional 790 shares during the period. 97.64% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of analysts have weighed in on the company. Needham & Company LLC reiterated a "buy" rating and issued a $64.00 target price on shares of LivaNova in a research note on Wednesday, September 3rd. Wolfe Research upgraded LivaNova from a "peer perform" rating to an "outperform" rating and set a $60.00 target price on the stock in a research note on Tuesday, May 20th. Barclays increased their target price on LivaNova from $55.00 to $58.00 and gave the stock an "equal weight" rating in a research note on Thursday, August 21st. Finally, Wall Street Zen upgraded LivaNova from a "buy" rating to a "strong-buy" rating in a research note on Saturday, August 9th. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Buy" and an average price target of $59.71.

LivaNova Stock Down 0.9%

LIVN stock traded down $0.52 during trading on Monday, reaching $55.70. 75,886 shares of the company traded hands, compared to its average volume of 695,294. LivaNova PLC has a 12 month low of $32.48 and a 12 month high of $58.91. The business has a 50 day simple moving average of $49.83 and a 200 day simple moving average of $44.09. The company has a market capitalization of $3.04 billion, a price-to-earnings ratio of -14.35 and a beta of 0.96. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.09 and a current ratio of 1.29.

LivaNova (NASDAQ:LIVN - Get Free Report) last issued its quarterly earnings data on Wednesday, August 6th. The company reported $1.05 earnings per share for the quarter, beating analysts' consensus estimates of $0.84 by $0.21. LivaNova had a positive return on equity of 14.57% and a negative net margin of 16.13%.The company had revenue of $352.50 million for the quarter, compared to the consensus estimate of $332.20 million. During the same quarter last year, the company earned $0.93 earnings per share. The firm's revenue for the quarter was up 10.6% compared to the same quarter last year. On average, equities research analysts anticipate that LivaNova PLC will post 2.85 earnings per share for the current fiscal year.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.